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Abstract
Background: The high complication rates of surgically implanted port catheter systems (SIPCS)
represents a major drawback in the treatment of isolated liver neoplasms by hepatic arterial
infusion (HAI) of chemotherapy. Interventionally implanted port catheter systems (IIPCS) have
evolved into a promising alternative that enable initiation of HAI without laparatomy, but
prospective data on this approach are still sparse. Aim of this study was to evaluate the most
important technical endpoints associated with the use of IIPCS for the delivery of 5-fluorouracil-
based HAI in patients with colorectal liver metastases in a phase 2-study, and to perform a non-
randomised comparison with a historical group of patients in which HAI was administered via
SIPCS.
Methods: 41 patients with isolated liver metastases of colorectal cancer were enrolled into a
phase II-study and provided with IIPCS between 2001 and 2004 (group A). The primary objective
of the trial was defined as evaluation of device-related complications and port duration. Results
were compared with those observed in a pre-defined historical collective of 40 patients treated
with HAI via SIPCS at our institution between 1996 and 2000 (group B).
Results:  Baseline characteristics were balanced between both groups, except for higher
proportions of previous palliative pre-treatment and elevated serum alkaline phosphatase in
patients of group A. Implantation of port catheters was successful in all patients of group A,
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whereas two primary failures were observed in group B. The frequency of device-related
complications was similar between both groups, but the secondary failure rate was significantly
higher with the use of surgical approach (17% vs. 50%, p < 0.01). Mean port duration was
significantly longer in the interventional group (19 vs. 14 months, p = 0.01), with 77 vs. 50% of
devices functioning at 12 months (p < 0.01). No unexpected complications were observed in both
groups.
Conclusion:  HAI via interventionally implanted port catheters can be safely provided to a
collective of patients with colorectal liver metastases, including a relevant proportion of
preatreated individuals. It appears to offer technical advantages over the surgical approach.
Background
The role of hepatic arterial infusion in patients with color-
ectal liver metastases has been frequently studied
throughout the past decades. More than a dozen of rand-
omized trials have been completed in which HAI with one
of the fluoropyrimidines floxuridine (FUDR) or 5-flour-
ouracil (5-FU) was compared to intravenous drug applica-
tion in patients with unresectable metastases or after
resection (reviewed in [1,2]). In summary, HAI largely
improved response rates in patients with unresectable dis-
ease and time to hepatic progression for both indications.
However, results are counterbalanced by the fact that
many of the trials did not reveal an increase in overall sur-
vival.
The reasons preventing a clear-cut survival benefit for HAI
have been discussed in detail elsewhere [1-6]. Small
patient numbers and inappropriate control groups may
have led to a misleading interpretations particularly in the
earlier trials. In addition, studies on intraarterial FUDR
revealed an excessively high rate of extrahepatic failure.
Adjacent trials completed in North America demonstrated
that systemic control rates of intraarterial FUDR can be
improved by combination with intravenous 5-FU [7,8]. In
contrast, European and Asian investigators aimed to opti-
mise results by taking the advantage of achieving systemic
drug concentrations and limiting hepatic toxicity as it is
provided by the intraarterial application of 5-FU [9,10].
Unlike hepatic arterial FUDR – which is usually delivered
through surgically implanted infusion pumps – regional
applications of 5-FU demand the use of external pumps,
due to the maximal drug concentration of 25 mg/ml, and
the resulting high volumes of medication. Therefore,
hepatic arterial 5-FU can only be delivered by intermittent
percutaneous access, or through hepatic arterial port sys-
tems. There is profound experience with the use of such
port catheters in a number of specialised treatment centres
worldwide. However, this technique is associated with a
considerable proportion of primary failure which has
been reported to approximate one third of patients sched-
uled for 5-FU-based HAI in recent multicenter trials
[9,11]. Once HAI has been started, port systems are asso-
ciated with a higher complication rate than surgically
implanted pumps, whereas secondary failure rates have
been reported to be similar (e.g. approximately half of
patients within the first 12 months of treatment) [12-14].
Today, it is widely accepted that the low performance level
of surgically implanted port catheters represents one
major reason why the theoretical advantage of 5-FU-based
HAI could not be transferred to convincing clinical
improvements so far.
Interventionally implanted port catheter systems (IIPCS)
have evolved into a promising alternative to surgically
implanted devices. IIPCS enable initiation of HAI without
laparatomy, and available data suggest favorable compli-
cation and failure rates. However, studies published so far
mainly focussed on either technical or clinical aspects of
treatment [10,15-20]. Thus it is still uncertain how these
devices compare to surgically implanted port catheters.
We here present an evaluation of technical endpoints
associated with the use of interventionally implanted
hepatic arterial port catheter systems for hepatic arterial
infusion of chemotherapy in a group of patients with
colorectal liver-only metastases, as well as, a non-ran-
domised comparison with those observed within a histor-
ical collective of patients provided with surgically
implanted devices.
Methods
Study design, patients' collectives and eligibility criteria
Patients with isolated liver metastases of colorectal cancer
were prospectively enrolled into a phase II-trial evaluating
technical complications associated with the use of inter-
ventionally implanted port catheters in patients with can-
cers confined to the liver (ClinicalTrials.gov Identifier:
NCT00356161). Complication rates and duration of
interventionally implanted port catheter systems, as well
as, reasons for primary and secondary device failure of the
first 41 colorectal cancer patients enrolled were assessed,
and compared with those observed in a pre-defined [21]
historical collective of 40 patients with colorectal liver
metastases provided with a surgically implanted port sys-
tem. The protocol and the evaluation presented hereinBMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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were approved by the local ethics committee, and a
detailed written informed consent was obtained from
every patient prior to treatment.
Group A: Interventionally implanted ports catheter systems (IIPCS)
Adult patients with histologically proven adenocarci-
noma of the colon or rectum, an ECOG performance sta-
tus of 0–2, and an estimated life expectancy of ≥ 6 months
were enrolled into a phase II-trial between March 2001
and May 2004 if they had irresectable liver metastases or
underwent hepatic resection or ablation in between the
last 8 weeks.
The primary objective was to evaluate the technical com-
plications associated with port implantation and adjacent
hepatic arterial infusion of chemotherapy, and of port
duration (time to port dysfunction). Secondary endpoints
included a comparison of these endpoints to those
observed within a historical collective of patients pro-
vided with a surgically implanted device, as well as, eval-
uation of a standardized approach of chemotherapy
application according to the different treatment indica-
tions, chemotherapy toxicity, response and survival rates.
Patients were excluded if they had a history of secondary
cancers in between the last three years, if they suffered
from extrahepatic metastases, were previously treated
with percutanoeous liver irradiation; had severe restric-
tions of vital organ function (in particular cardiovascular
or liver disease), other severe medical conditions or con-
traindications against the cytostatic drugs to be applied.
The port implantation procedure has been described in
detail by Ricke et al. ([18]). It consisted of the placement
of a standard angiography catheter in the hepatic artery
and subcutaneous connection to a port system (Titakath;
Innovent, Hürth, Germany) placed inferior to the groin by
using a titanium connector (Arrow, Reading, PA, USA).
Patency and integrity of the system was documented by
digital subtraction angiography (DSA) and comple-
mented by a scintigraphy using (99 m)Tc-labelled macro-
aggregated albumin if necessary. DSA was repeated before
each treatment course. In a subset of patients, port pat-
ency was additionally assessed by SPECT-CT [22].
Group B: Patients with surgically implanted port catheter systems 
(SIPCS)
Group B consisted of all colorectal cancer patients pro-
vided with SIPCS which were assigned to HAI within the
scope of a standardised protocol between 1996 and the
introduction of IIPCS in 2000. After identifying patients
by database query, a retrospective evaluation of medical
records was performed with regard to the same endpoints
as for patients of group A before the start of above-men-
tioned phase II trial [21]. Patients included into one mul-
ticenter trial were excluded due to the different
chemotherapy protocol applied [23]. Three of the patients
included had already been communicated as case-reports
[24,25].
Implantation of the device was performed in the scope of
laparatomy (as described by [9]), with the port chamber
being placed subcutaneously overlying the right lower
ribs. Total liver perfusion was controlled intraoperatively
with the injection of fluorescein dye (5 mL). Postopera-
tively, patency and integrity of the port system was docu-
mented by DSA, complemented by a scintigraphy using
(99 m)Tc-labeled macroaggregated albumin if necessary.
Interventions
Hepatic arterial infusion of chemotherapy
Because the patient population was anticipated to be het-
erogenously with respect to pretreatment and treatment
indications, the phase II-protocol on IIPCS allowed differ-
ent chemotherapy regimen based on the protocol of the
German Cooperative Group on Liver Metastases as previ-
ously described [18,24]. Patients not pretreated in a palli-
ative intent were assigned to intra-arterial folinic acid
(170 mg/m2, d1-5, q28) followed by intra-arterial 5-FU
(600 mg/m2, 120 minutes). The only difference between
both groups with regard to chemotherapy was that FA was
delivered as a mixture of sodium folinate and 5-FU over
120 min. in group A, and consecutively as calcium foli-
nate over 30 min. followed 5-FU (120 min) in group B. A
5-FU dose escalation of 10% per cycle was performed
until the occurrence of adverse reactions (WHO I-II). In
patients with hepatic disease progression while undergo-
ing this treatment, regional chemotherapy was escalated
by adding mitomycin (8 mg/m2, 120 minutes) on day 1
of each cycle. Since July 2002, patients in group A were
preferentially switched to weekly FA/5-FU complemented
by intraarterial oxaliplatin (50 mg/m2, 120 minutes) for 6
of 8 weeks instead, whereas patients with extrahepatic dis-
ease progression were scheduled to weekly FA/5-FU com-
plemented by weekly intravenous irinotecan (125 mg/m2,
60–90 minutes) for 3 out of 4 weeks. As patients of group
A started HAI before the introduction of oxaliplatin and
irinotecan, folinic acid and continuous infusional 5-FU at
a dose of 2.6–3,6 g/m2 applied over 4–48 h was consid-
ered as salvage treatment. The final decision on the chem-
otherapy schedule was at the physicians' discretion and
based on the individual pretreatments.
Evaluations
Pretreatment evaluation and follow-up
Each patients' history was recorded and clinical examina-
tion was performed. In patients of group A, this was done
prospectively within the 14 days preceding the first chem-
otherapy application, as well as, haematologic and bio-
chemical laboratory analyses were performed. ImagingBMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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procedures comprised an abdominal CT or MRT and
chest-x-ray or CT in every patient. Clinical evaluation, a
full blood count and clinical chemistry were repeated at
least monthly. Assessment of toxicity was performed after
every treatment course according to WHO-criteria. In
patients of both groups, information on pretreatment and
clinical course were extracted from the patients medical
records, and supplemented by systematic queries of find-
ings recorded on the databases of the Surgical and Radio-
logical Clinic.
Response evaluation according to WHO criteria and eval-
uation of tumor markers were repeated at least every 3
months during treatment. After completion of therapy,
patients were followed up by clinical investigations every
3 months, complemented by response evaluation until
disease progression, initiation of salvage treatment or
death. The efficacy analyses included objective response
rates, as well as, progression free- and overall survival.
Treatment was interrupted if irreversible loss of function
of the port device, WHO toxicity IV° (except for haemato-
toxicity), or disease progression after escalation of treat-
ment occurred. The dosage of cytostatics was reduced if
WHO-toxicity III° or haematotoxicity III/IV° appeared in
between of two treatment courses or toxicity >WHO I°
was ongoing on the first day of the following cycle (except
for leukocytopenia: >WHO II° and thrombocytopenia:
>II°). For combination regimens, it was at the physicians
discretion to reduce all or only one dosage of the com-
pounds.
Due to the standardized pretreatment assessment of
patients provided with surgically implanted port cathe-
ters, the retrospective evaluation of the patients' record,
documentation, and analyses of endpoints of patients of
group B were largely the same as for group A. Data analy-
ses had already been completed before the initiation of
the phase II-trial [21].
Port complications, port duration, and toxicity
Device-related adverse events were assessed from the time
point of successful implantation. Patency and integrity of
the port system was documented by DSA performed
before every treatment course, complemented by a scintig-
raphy of the liver with Tc-99 m labeled macroaggregated
albumine when gross pathological findings were
observed. Port duration was defined as functional device
with or without revision, but without need for complete
system explantation. Patients in which HAI was stopped
because of disease progression were censored at the last
application of HAI.
Statistical evaluations
Differences between proportions were analyzed by chi-
square tests. Mann-Whitney tests were used to compare
quantitative and ordinal variables. Univariate analysis of
port duration was calculated according to the Kaplan-
Meier method, and comparisons between groups were
calculated by Log-Rank tests. A two-sided p-value less than
0.05 was considered to indicate significance for all tests.
All analyses were performed by using the SPSS 12.0 soft-
ware package.
Results
Patients' and treatment characteristics
Baseline characteristics were similar between patients
enrolled into group A and those of group B. However,
higher rates of palliative pretreatment and elevated serum
alkaline phosphatase indicate a rather unfavorable prog-
nosis for patients of group A (Table 1).
The proportions of patients with nonresectable liver
metastases and those who had undergone hepatic resec-
tion or hepatic ablation procedures within the past 8
weeks (and thus were treated in an "adjuvant" intent)
were comparable between groups A and B (Table 2). Port
implantation was successful and regional therapy was
started in all (n = 41) patients of group A (100%), whereas
primary port failure due to hepatic artery thrombosis was
recorded in two out of 40 patients of group B. The rate of
patients starting HAI as combination chemotherapy was
significantly higher in patients of group A than of group B.
The same held true for patients who received either oxali-
platin or irinotecan during their course of treatment
(Table 2).
Revisions of the port system were required in 23 patients
of group A, and were all carried out in an interventional
way. Thereby, a dislocation of the catheter tip was the
most common reason for first revision (n = 8), followed
by leakage/extravasation (n = 5), thrombus/embolisation
(n = 5), disconnection of catheter and port chamber (n =
3), catheter occlusion (n = 1), port chamber infection (n
= 1). In group B, a surgical revision of the device was per-
formed in 4 patients, due to rotation (n = 2)/dislocation
(n = 1) of the port chamber, or dislocation of catheter tip
(n = 1). Taken together, the number of revisions were
more frequent in group A than in group B, whereas the
rates of patients requiring local thrombolytic therapy were
comparable.
The numbers of patients who received six courses of foli-
nic acid and 5-FU in an adjuvant intent were similar in
both groups (8/10 in group A vs. 7/9 pts. in group B). All
eight patients of group A had a functioning regional
chemotherapy device at post-therapeutic restaging,
whereas port failure was diagnosed immediately afterBMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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Table 2: Treatment characteristics
Group A: Interventional Group B: Surgical p-value*
Intention of treatment:
"adjuvant" after resection/ablation 10 9**
palliative 31 31
Type of first HAI – chemotherapy:
none (primary port failure) 0 2
First-line FA/5-FU only 27 32
First-line combination 14 6 0.046
Switched to 2nd-line HAI 16 12
Switched to 3rd-line HAI 3 2
Received HAI with MMC (any line) 8 7
Received HAI with L-OHP (any line) 16 1 < 0.001
Received HAI and i.v. CPT-11 (any line) 9 0 < 0.001
Complications and revisions
≥ 1 complication 26 30
≥ 2 complications 9 11
≥ 1 revision 23 4 < 0.001
≥ 1 thrombolytic therapy 7 11
Reason for termination of HAI:
regular/ongoing 12 4 0.029
disease progression 19 14
port complication 7 20 < 0.001
chemotherapy-related toxicity 1 1
withdrawal 2 0
* only significant values are indicated
** 8 patients of group A and 7 patients of group B completed 6 courses of adjuvant treatment (see text for further details)
FA = folinic acid; 5-FU = 5-fluorouracil; MMC = mitomycin C; L-OHP = oxaliplatin; CPT-11 = irinotecan
Table 1: Patients' characteristics
Group A: Interventional Group B: Surgical
Age (median/range) 60 (28–77) 59 (31–71)
Sex (f/m) 18/23 14/26
Primary tumour:
colon/rectum 27/14 26/14
grading (G1/G2/G3/Gx) 1/26/12/2 0/29/10/1
Number of liver metastases:
solitary/2–4/> 4 12/3/26 16/3/21
Occurrence of metastases
synchron/metachron 19/22 24/16
Pre-treatment:
Resection of primary 40 40
Hepatic resection/ablation 17 11
Adjuvant radiotherapy/chemotherapy radiochemotherapy 13 11
Palliative chemotherapy 17 9
more than 1 palliative pre-treatment * 9 0
Elevated CEA 29 32
Elevated Alkaline phosphatase * 30 16
* only significant values are indicatedBMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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completion of adjuvant chemotherapy in three additional
patients of group B. At a mean observation time of 8.0 vs.
8.4 months (p = 0.73), the proportion of patients of group
A who regularly completed treatment with an intact
regional chemotherapy device, or had a functioning port
system at the end of the study, was significantly higher
than in group B. In addition, the rate of patients in which
HAI had to be terminated due to terminal device dysfunc-
tion was significantly lower (Table 2).
Comparison of port complications and port duration
In group A, a total of 39 device-related complications were
recorded in 26 patients (63%). Those mostly comprised
vascular events such as dislocation of the catheter tip, or
thrombosis of the hepatic artery or one of its branches. 9
patients experienced more than one complication. In
group B, the respective rates were only slightly higher
(tables 2 and 3).
Complications of vascular origin were less common in
group A than in group B, although dislocations of the
catheter tip were more frequently observed in group A
(table 3). However, the latter could be regularly revised,
and the incidence of hepatic arterial thrombosis was
lower than in group B. In addition, hepatic arterial steno-
sis (defined as angiographically detected stenosis without
thrombotic material or signs of dissection at the catheter
tip) was exclusively observed in 7 patients of group B
(table 3). The higher vascular complication rate in group
B translated into a significant higher proportion of treat-
ment-limiting vascular complications (table 4).
Rates of patients with functional devices at 12 months
were 77 vs. 50% (p < 0.01). The mean port duration was
19 months for patients in group A and 14 months for
patients of group B (log-rank p = 0.01) (figure 1).
Chemotherapy toxicity
WHO grade 3 adverse events were observed in patients of
group A/B as follows: Nausea/emesis 6/3, mucositis 6/3,
Diarrhoe 7/5, anemia 1/0, leucocytopenia 7/2, thrombo-
cytopenia 1/0. Episodes of grade 4 toxicity comprised
mucositis 1/0 and thrombocytopenia 1/0, anemia 1/0.
Severe abdominal pain occurred in 4 patients of group A.
Gastric or duodenal ulcer due to treatment-related
abdominal pain was diagnosed in 1/2 patients. No severe
hepatic toxicity was observed.
Discussion
Up to now, only few reports on the use of IIPCS in any
pre-defined tumor entity or treatment indication are avail-
able. Indeed, studies dealing with technical considera-
tions in detail mostly evaluated patients with different
cancers (reviewed by Heinrich et al [14]), whereas studies
evaluating novel HAI-approaches for colorectal cancer
patients did not give a detailed description on technical
aspects [10,17]. With this report, we give a detailed
description on the technical aspects of HAI provided via
IIPCS in patients with colorectal liver metastases for the
first time.
Probably most important, we demonstrated that all
patients scheduled for HAI via an interventionally
implanted port catheter could be provided with a func-
tioning device. The virtual absence of primary device fail-
ure with the use of IIPCS has been described earlier by
others (reviewed in [14]) and us [18]. However, it is
remarkable that we were able to reproduce such a result in
Table 3: Overall port complications
GROUP A: Interventional GROUP B: Surgical p value
Number of pts./treatment courses 41/260 40/245
Abs. % Abs. %
Number of complications 39 100.0 45 100.0
vascular 25 64.1 36 77.8 0.103
Dislocation of catheter tip 8 20,5 3 6.7 0.061
Thrombosis (total) 7 17.9 10 22.2 0.627
Thrombosis (partial)/embolism 6 15.4 9 20.0 0.582
Stenosis 0 0.0 7 15.6 0.010
Dissection 3 7.7 6 13.3 0.404
Reflux 1 2.6 1 2.2 0.918
non vascular 14 38.5 9 22.2 0.103
Leakage/extravasation 4/1 12.8 3/1 8.9 0.561
Disconnection/rupture 4/1 12.8 0/1 2.2 0.060
Rotation of port chamber 0 0.0 2 4.4 0.183
Infection of port chamber 3 7.7 1 2.2 0.240
others 1 2.6 1 2.2 0.918BMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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a prospective manner in a collective of patients with color-
ectal liver metastases in which 41% of patients were pre-
treated by hepatic resection or ablation, and in which the
same percentage had previously received at least one pal-
liative line of chemotherapy.
The rate of catheter-associated complications observed
with the use of interventionally implanted port devices
has been reported to range from 4–56% [14]. In the larg-
est trial on IIPCS available on so far, the authors calcu-
lated a rate of 25% of device failures, but did not add a
detailed description of actual complications to their
report [10]. In the present study, the rate of patients expe-
riencing at least one device-related complication was con-
siderably higher (63%), but a high proportion of events
could be successfully corrected by interventional revi-
sions. This particular holds true for dislocations of the
catheter tip and complications affecting the connection of
the catheter and port chamber which did not result in ter-
minal device failure in any of the patients affected. In
summary, our rate of 17% device-related treatment inter-
ruptions with the use of interventionally implanted port
catheters compares favourable with most previous publi-
cations.
In a larger perspective, results achieved with the use of
IIPCS have to compare with those observed with surgi-
cally implanted devices. Therefore, a substantial part of
our presentation deals with the comparison of technical
endpoints between the IIPCS and SIPCS for the delivery of
5-fluorouracil-based HAI in patients with colorectal liver
metastases. For SIPCS, previous studies have reported
major complication rates in the range of 22–48%, and
port durations of 7–13 months [12-14]. In our SIPCS
group, the mean device duration of 14 months compares
favourable with this data, despite the relatively high fail-
ure rate of secondary device failure.
The direct comparison of device-related complications
did not reveal significant differences between our group of
patients on the first sight. However, there was a trend
towards a higher rate of revisions in the interventional
group which was mostly due to dislocations of the cathe-
ter tip and non-vascular events. Those catheter disloca-
tions are mostly manageable from a technical point of
view, but one has to keep in mind that extrahepatic deliv-
ery of chemotherapy may result in decreased efficacy and
occurrence of additional side effects. Indeed, episodes of
severe abdominal pain were exclusively observed in
patients of the IIPCS-group of our study, whereas the rates
of gastric and duodenal ulcers was similar in both groups.
On the contrary, occurrence of hepatic arterial stenosis
Comparison of port duration between interventionally and  surgically implanted devices Figure 1
Comparison of port duration between interventionally and 
surgically implanted devices.
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Table 4: Treatment-limiting port complications
GROUP A: Interventional (n = 41) GROUP B: Surgical (n = 40) p-value
Abs. % Abs. %
vascular 5 12.2 15 37.5 0.008
Thrombosis 5 12.2 9 22.5 0.220
Hepatic arterial stenosis 0 0 2 5.0 0,147
Dislocation of catheter tip 0 0 2 5.0 0.147
Reflux gastric/duodenal artery 0 0 1 2.5 0.308
Dissection hepatic artery 0 0 1 2.5 0.308
non vascular 24 . 9 5 1 2 . 5 0.222
Leakage/extravasation 0 0 3 7.5 0.074
Rotation of port chamber 0 0 1 2.5 0.308
Infection of port chamber 2 4.9 1 2.5 0.571BMC Cancer 2007, 7:69 http://www.biomedcentral.com/1471-2407/7/69
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and thrombosis represented the major technical obstacle
with the use of SIPCS. This may be explained by the fact
that the catheter tip is fixed by suture within the hepatic
artery with this technique, a fact that also makes interven-
tional revisions impossible or at least problematic in most
cases. As a result, there was a significantly higher rate of
treatment-limiting vascular complications in the surgical
than in the interventional group, resulting in a significant
difference in port duration.
Another point of consideration is the difference in the
application of folinic acid between both groups. In group
A, a mixture of sodium folinate and 5-FU was adminis-
tered, whereas a sequential application of calcium folinate
and 5-FU was employed in group B. It seems very unlikely
that this different practice has contributed to the differ-
ence in port complications, although no randomized
comparisons on this topic are available either for the
intraarterial nor the intravenous application [26,27]. Our
results – at least – demonstrate that the combined use of
sodium folinate and 5-FU in hepatic arterial infusion is
not associated with a higher rate of device-related or vas-
cular complications.
Comparing the baseline characteristics characteristics
between both of our groups, the distribution of some
items (elevated AP, number of pretreatments) indicate a
rather unfavorable prognosis for the interventional group.
This is underlined by the higher percentage of patients
who primarily received a combination regimen, even
though other factors – such as the introduction of novel
drug combinations – may have contributed to this phe-
nomenon. Due to these differences between both groups,
it does not seem appropriate to compare response rates or
other parameters of efficacy. However, it is important to
mention that we did not observe unexpected complica-
tions in the scope of the implantation procedure or adja-
cent application of HAI in the IIPCS group. In this context,
the absence of severe hepatotoxicity and biliary cirrhosis
is in line with the results of other, larger studies on the
regional use of 5-fluorouracil, where no respective epi-
sodes or treatment interruptions due to local side-effects
have been reported [9,10]. Given the high performance
rate of such devices on the one, and the fact that their
implantation does not require laparatomy on the other
hand, it appears that IIPCS enables the implementation of
HAI even in colorectal cancer populations with a relevant
percentage of heavily pretreated patients.
When interpreting these results, the non-randomised
fashion of treatment allocation and the lack of compari-
sons with regard to oncological endpoints have to be con-
sidered. Indeed, we strictly focussed our phase II-trial on
HAI provided through IIPCS on technical endpoints in a
rather descriptive way, and aimed to work out at least an
equivalence with the surgical approach within relatively
heterogen collectives of patients with colorectal liver
metastases. Being surprised about the clear result in favour
of the interventional approach, the authors believe that
data presented herein may be best understood as explora-
tory ones. They indicate a certain superiority of interven-
tional port catheter implantation over the surgical
approach with regard to both, technical failure rates and a
broadened indication spectrum. Results seem to justify
further evaluation of this topic and may serve as basis for
the planning of future trials.
Conclusion
HAI via interventionally implanted port catheters can be
safely provided to a prospective collective of patients with
colorectal liver metastases, including a relevant propor-
tion of pre-treated individuals. It appears to offer techni-
cal advantages over the surgical approach.
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